| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VIGL | Stock Option Award (Right to Buy) | Disposed to Issuer | -$73K | -7.58K | -100% | $9.63 | 0 | May 3, 2024 | Common Stock | 7.58K | $16.13 | Direct | F1, F2, F3 |
| transaction | VIGL | Stock Option Award (Right to Buy) | Award | $0 | +7.58K | $0.00 | 7.58K | May 3, 2024 | Common Stock | 7.58K | $3.03 | Direct | F1, F2, F3, F4 | |
| transaction | VIGL | Stock Option Award (Right to Buy) | Disposed to Issuer | $0 | -12.2K | -100% | $0.00* | 0 | May 3, 2024 | Common Stock | 12.2K | $3.10 | Direct | F1, F3, F5 |
| transaction | VIGL | Stock Option Award (Right to Buy) | Award | $0 | +12.2K | $0.00 | 12.2K | May 3, 2024 | Common Stock | 12.2K | $3.03 | Direct | F1, F3, F4, F5 | |
| transaction | VIGL | Stock Option Award (Right to Buy) | Disposed to Issuer | -$74K | -9.71K | -100% | $7.62 | 0 | May 3, 2024 | Common Stock | 9.71K | $11.87 | Direct | F1, F3, F6 |
| transaction | VIGL | Stock Option Award (Right to Buy) | Award | $0 | +9.71K | $0.00 | 9.71K | May 3, 2024 | Common Stock | 9.71K | $3.03 | Direct | F1, F3, F4, F6 | |
| transaction | VIGL | Stock Option Award (Right to Buy) | Disposed to Issuer | $0 | -13.9K | -100% | $0.00* | 0 | May 3, 2024 | Common Stock | 13.9K | $10.00 | Direct | F1, F3, F7 |
| transaction | VIGL | Stock Option Award (Right to Buy) | Award | $0 | +13.9K | $0.00 | 13.9K | May 3, 2024 | Common Stock | 13.9K | $3.03 | Direct | F1, F3, F4, F7 |
| Id | Content |
|---|---|
| F1 | On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the"Effective Date"). Except for the new exercise price (see footnote 4 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of theExchange Act, as applicable. |
| F2 | This stock option award was issued pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation and the shares subject to this stock option award are fully vested and exercisable as of the date hereof. |
| F3 | The Reporting Person is a member of Atlas Venture Associates XII, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
| F4 | The exercise price of the stock option award is $3.03 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event (as defined in the 2021 Plan) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2021 Plan) by the Company other than for Cause (as defined in the 2021 Plan) or due to the Reporting Person's death or disability. |
| F5 | This stock option award was issued pursuant to the 2021 Plan and the shares subject to this stock option award are fully vested and exercisable as of the date hereof. |
| F6 | This stock option award was issued pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation and the shares subject to this stock option award are fully vested and exercisable asof the date hereof. |
| F7 | This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable upon the earlier to occur of (i) June 7, 2024 and (ii) the next annual meeting of the Issuer's stockholders. |